20s Proteasome-United States Market Status and Trend Report 2013-2023
Report Summary
20s Proteasome-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on 20s Proteasome industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of 20s Proteasome 2013-2017, and development forecast 2018-2023
Main market players of 20s Proteasome in United States, with company and product introduction, position in the 20s Proteasome market
Market status and development trend of 20s Proteasome by types and applications
Cost and profit status of 20s Proteasome, and marketing status
Market growth drivers and challenges
The report segments the United States 20s Proteasome market as:
United States 20s Proteasome Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States 20s Proteasome Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Marizomib
Oprozomib
Carfilzomib
VPEA-002
Others
United States 20s Proteasome Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Colon Cancer
Lymphoma
Malignant Glioma
Neuroendocrine Cancer
Ovarian Cancer
Others
United States 20s Proteasome Market: Players Segment Analysis (Company and Product introduction, 20s Proteasome Sales Volume, Revenue, Price and Gross Margin):
Amgen Inc
Celgene Corp
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
20s Proteasome-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on 20s Proteasome industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of 20s Proteasome 2013-2017, and development forecast 2018-2023
Main market players of 20s Proteasome in United States, with company and product introduction, position in the 20s Proteasome market
Market status and development trend of 20s Proteasome by types and applications
Cost and profit status of 20s Proteasome, and marketing status
Market growth drivers and challenges
The report segments the United States 20s Proteasome market as:
United States 20s Proteasome Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States 20s Proteasome Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Marizomib
Oprozomib
Carfilzomib
VPEA-002
Others
United States 20s Proteasome Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Colon Cancer
Lymphoma
Malignant Glioma
Neuroendocrine Cancer
Ovarian Cancer
Others
United States 20s Proteasome Market: Players Segment Analysis (Company and Product introduction, 20s Proteasome Sales Volume, Revenue, Price and Gross Margin):
Amgen Inc
Celgene Corp
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
1.1 Definition of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform in This Report
1.2 Commercial Types of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
1.2.1 PQR-514
1.2.2 KA-2237
1.2.3 GSK-2636771
1.2.4 BAY-1082439
1.2.5 Others
1.3 Downstream Application of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
1.3.1 Gastric Cancer
1.3.2 Metastatic Colorectal Cancer
1.3.3 Myelofibrosis
1.3.4 Renal Cell Carcinoma
1.3.5 Others
1.4 Development History of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
1.5 Market Status and Trend of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform 2013-2023
1.5.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Status and Trend 2013-2023
1.5.2 Regional Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform 2013-2017
2.2 Production Market of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.2.1 Production Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.2.2 Production Value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.3 Demand Market of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.4 Production and Demand Status of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.4.1 Production and Demand Status of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions 2013-2017
2.4.2 Import and Export Status of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Types
3.2 Production Value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Types
3.3 Market Forecast of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Downstream Industry
4.2 Market Forecast of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
5.1 Global Economy Situation and Trend Overview
5.2 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Downstream Industry Situation and Trend Overview
CHAPTER 6 PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Major Manufacturers
6.2 Production Value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Major Manufacturers
6.3 Basic Information of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Major Manufacturer
6.3.2 Employees and Revenue Level of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca Plc
7.1.1 Company profile
7.1.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.1.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of AstraZeneca Plc
7.2 Bayer AG
7.2.1 Company profile
7.2.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.2.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Bayer AG
7.3 Curis Inc
7.3.1 Company profile
7.3.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.3.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Curis Inc
7.4 GlaxoSmithKline Plc
7.4.1 Company profile
7.4.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.4.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.5 Karus Therapeutics Ltd
7.5.1 Company profile
7.5.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.5.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Karus Therapeutics Ltd
7.6 Novartis AG
7.6.1 Company profile
7.6.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.6.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Novartis AG
7.7 PIQUR Therapeutics AG
7.7.1 Company profile
7.7.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.7.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of PIQUR Therapeutics AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
8.1 Industry Chain of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
9.1 Cost Structure Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
9.2 Raw Materials Cost Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
9.3 Labor Cost Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
9.4 Manufacturing Expenses Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
CHAPTER 10 MARKETING STATUS ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform in This Report
1.2 Commercial Types of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
1.2.1 PQR-514
1.2.2 KA-2237
1.2.3 GSK-2636771
1.2.4 BAY-1082439
1.2.5 Others
1.3 Downstream Application of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
1.3.1 Gastric Cancer
1.3.2 Metastatic Colorectal Cancer
1.3.3 Myelofibrosis
1.3.4 Renal Cell Carcinoma
1.3.5 Others
1.4 Development History of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
1.5 Market Status and Trend of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform 2013-2023
1.5.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Status and Trend 2013-2023
1.5.2 Regional Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform 2013-2017
2.2 Production Market of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.2.1 Production Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.2.2 Production Value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.3 Demand Market of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.4 Production and Demand Status of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions
2.4.1 Production and Demand Status of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions 2013-2017
2.4.2 Import and Export Status of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Types
3.2 Production Value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Types
3.3 Market Forecast of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Downstream Industry
4.2 Market Forecast of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
5.1 Global Economy Situation and Trend Overview
5.2 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Downstream Industry Situation and Trend Overview
CHAPTER 6 PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Major Manufacturers
6.2 Production Value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Major Manufacturers
6.3 Basic Information of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Major Manufacturer
6.3.2 Employees and Revenue Level of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca Plc
7.1.1 Company profile
7.1.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.1.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of AstraZeneca Plc
7.2 Bayer AG
7.2.1 Company profile
7.2.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.2.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Bayer AG
7.3 Curis Inc
7.3.1 Company profile
7.3.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.3.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Curis Inc
7.4 GlaxoSmithKline Plc
7.4.1 Company profile
7.4.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.4.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.5 Karus Therapeutics Ltd
7.5.1 Company profile
7.5.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.5.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Karus Therapeutics Ltd
7.6 Novartis AG
7.6.1 Company profile
7.6.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.6.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of Novartis AG
7.7 PIQUR Therapeutics AG
7.7.1 Company profile
7.7.2 Representative Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product
7.7.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales, Revenue, Price and Gross Margin of PIQUR Therapeutics AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
8.1 Industry Chain of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
9.1 Cost Structure Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
9.2 Raw Materials Cost Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
9.3 Labor Cost Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
9.4 Manufacturing Expenses Analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform
CHAPTER 10 MARKETING STATUS ANALYSIS OF PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT BETA ISOFORM
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
